Baillie Gifford & Co
DNA icon

Baillie Gifford & Co’s Ginkgo Bioworks DNA Stock Holding History

Baillie Gifford & Co’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7M Hold
2,391,649
– – 0.02% 176
2026
Q1 		$14.7M Hold
2,391,649
– – 0.02% 196
2025
Q4 		$19.9M Sell
2,391,649
-843,605
-26% -$9.08M 0.02% 185
2025
Q3 		$47.2M Sell
3,235,254
-40,797
-1% -$488K 0.03% 153
2025
Q2 		$36.9M Sell
3,276,051
-74,840
-2% -$580K 0.03% 164
2025
Q1 		$19.1M Sell
3,350,891
-6,495
-0.2% -$66.2K 0.02% 182
2024
Q4 		$33M Sell
3,357,386
-1,195
-0% -$10.2K 0.03% 165
2024
Q3 		$27.4M Sell
3,358,581
-2,066
-0.1% -$20.7K 0.02% 167
2024
Q2 		$44.9M Sell
3,360,647
-2,464,345
-42% -$73.5M 0.04% 145
2024
Q1 		$270M Sell
5,824,992
-82,313
-1% -$4.26M 0.21% 89
2023
Q4 		$399M Sell
5,907,305
-62,916
-1% -$3.85M 0.32% 70
2023
Q3 		$432M Sell
5,970,221
-56,814
-0.9% -$4.54M 0.39% 57
2023
Q2 		$448M Sell
6,027,035
-44,672
-0.7% -$2.64M 0.38% 59
2023
Q1 		$323M Sell
6,071,707
-32,709
-0.5% -$2.07M 0.29% 76
2022
Q4 		$413M Buy
6,104,416
+1,002,495
+20% +$92.2M 0.43% 64
2022
Q3 		$637M Sell
5,101,921
-31,274
-0.6% -$3.73M 0.66% 41
2022
Q2 		$489M Buy
5,133,195
+939,378
+22% +$115M 0.5% 57
2022
Q1 		$676M Buy
4,193,817
+1,457,563
+53% +$284M 0.47% 59
2021
Q4 		$910M Buy
2,736,254
+461,184
+20% +$219M 0.5% 57
2021
Q3 		$1.05B Buy
+2,275,070
New +$1.11B 0.55% 51

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co's DNA Position: Q2 2026 in Review

Baillie Gifford & Co held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 2,391,649 shares worth $23.7M. The position accounts for 0.02% of the portfolio, ranked #176.

Baillie Gifford & Co first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.05B in Q3 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Baillie Gifford & Co held 2,391,649 shares of Ginkgo Bioworks worth $23.7M as of Q2 2026.
  • Baillie Gifford & Co left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up 0.02% of Baillie Gifford & Co's portfolio in Q2 2026, its #176 holding.
  • Baillie Gifford & Co first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • Baillie Gifford & Co's Ginkgo Bioworks position peaked at $1.05B in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.